Evidence map›Paper›PMID 35927391›Full record

ArticleNPJ breast cancer2022

The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer.

Edoardo Isnaldi, François Richard, Maxim De Schepper, Sophia Leduc, Marion Maetens, Tatjana Geukens, Karen Van Baelen, Ha-Linh Nguyen, Ghizlane Rouas, Gabriele Zoppoli and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 4 countries.

Edoardo Isnaldi *KU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, B-3000, Leuven, Belgium.ORCID http://orcid.org/0000-0002-1055-7254
François Richard *KU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, B-3000, Leuven, Belgium.ORCID http://orcid.org/0000-0003-4353-3619
Maxim De SchepperKU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, B-3000, Leuven, Belgium.
Sophia LeducKU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, B-3000, Leuven, Belgium.
Marion MaetensKU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, B-3000, Leuven, Belgium.
Tatjana GeukensKU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, B-3000, Leuven, Belgium.ORCID http://orcid.org/0000-0001-8828-8739
Karen Van BaelenKU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, B-3000, Leuven, Belgium.ORCID http://orcid.org/0000-0002-5700-3574
Ha-Linh NguyenKU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, B-3000, Leuven, Belgium.ORCID http://orcid.org/0000-0002-2538-7657
Ghizlane RouasUniversité Libre de Bruxelles, Institut Jules Bordet, J.C. Heuson Breast Cancer Translational Research Laboratory, B-1000, Brussels, Belgium.
Gabriele ZoppoliDepartment of Internal Medicine and Medical Specialties, University of Genoa, IT-16132, Genoa, Italy.
Fatima CardosoChampalimaud Clinical Center-Champalimaud Foundation, Breast Unit, P-1400-038, Lisbon, Portugal.ORCID http://orcid.org/0000-0002-6692-2249
Christos SotiriouUniversité Libre de Bruxelles, Institut Jules Bordet, J.C. Heuson Breast Cancer Translational Research Laboratory, B-1000, Brussels, Belgium.ORCID http://orcid.org/0000-0002-5745-9977
Denis LarsimontUniversité Libre de Bruxelles, Institut Jules Bordet, Pathology Department, B-1000, Brussels, Belgium.
Giuseppe FlorisUniversity Hospitals Leuven, Department of Pathology, B-3000, Leuven, Belgium.ORCID http://orcid.org/0000-0003-2391-5425
Elia Biganzoli *Unit of Medical Statistics, Biometry and Epidemiology, Department of Biomedical and Clinical Sciences (DIBIC) "L. Sacco" & DSRC, LITA Vialba campus, Università degli Studi di Milano, IT-20157, Milan, Italy.ORCID http://orcid.org/0000-0003-1202-5873
Christine Desmedt *KU Leuven, Department of Oncology, Laboratory for Translational Breast Cancer Research, B-3000, Leuven, Belgium. christine.desmedt@kuleuven.be.ORCID http://orcid.org/0000-0002-5223-5579
KU Leuven · BEUniversité Libre de Bruxelles · BEBreast Cancer Research Foundation · USChampalimaud Foundation · PTOspedale Policlinico San Martino · ITUniversity of Genoa · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The impact of adiposity on the efficacy of endocrine treatment in patients with estrogen receptor positive breast cancer is poorly investigated. Here, we retrospectively investigated in a cohort of 56 patients whether body mass index and/or mammary adiposity are associated with anti-proliferative response in the neoadjuvant setting. Anti-proliferative response was defined as high Ki67 at baseline (Ki67

Identifiers

PMID35927391
PMCPMC9352750
OpenAlexW4289855776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.